KCNJ11E23K variant is associated with the therapeutic effect of sulphonylureas in Chinese type 2 diabetic patients

Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated Type 2 diabetic patients

(2012) Georgia Ragia et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

KCNJ11 gene E23K variant and therapeutic response to sulfonylureas

(2011) Martin Javorsky et al.   European Journal of Internal Medicine

Metabolic Control in Type 2 Diabetes Is Associated with Sulfonylurea Receptor-1 (SUR-1) but Not with KCNJ11 Polymorphisms

(2009) Nora Nikolac et al.   ARCHIVES OF MEDICAL RESEARCH

Pharmacogenetics and future strategies in treating hyperglycaemia in diabetes

(2009) Ewan et al.   Frontiers in Bioscience-Landmark

PPARG, KCNJ11, CDKAL1, CDKN2A-CDKN2B, IDE-KIF11-HHEX, IGF2BP2 and SLC30A8 Are Associated with Type 2 Diabetes in a Chinese Population

(2009) Cheng Hu et al.   PLoS One

Association ofKCNJ11andABCC8genetic polymorphisms with response to repaglinide in Chinese diabetic patients1

(2008) Ya-yi HE et al.   ACTA PHARMACOLOGICA SINICA

Ser1369Ala Variant in Sulfonylurea Receptor Gene ABCC8 Is Associated With Antidiabetic Efficacy of Gliclazide in Chinese Type 2 Diabetic Patients

(2008) Y. Feng et al.   DIABETES CARE